Ibrolipim NO-1886|cas:133208-93-2|西域试剂

Ibrolipim NO-1886,99.21%

产品编号：Bellancom-117549| CAS NO：133208-93-2| 分子式：C₁₉H₂₀BrN₂O₄P| 分子量：451.25

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-117549	￥500.00	杭州北京（现货）
Bellancom-117549	￥900.00	杭州北京（现货）
Bellancom-117549	￥1400.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Ibrolipim NO-1886

产品介绍

Ibrolipim (NO-1886) 是一种口服活性的脂蛋白脂肪酶 (LPL) 激活剂。 Ibrolipim 可降低血浆甘油三酸酯，增加高密度脂蛋白胆固醇水平。 Ibrolipim 具有肾保护和降血脂的作用。

生物活性

Ibrolipim (NO-1886) is an orally active lipoprotein lipase (LPL)-promoting agent. Ibrolipim decreases plasma triglycerides, increases high-density lipoprotein cholesterol levels. Ibrolipim has renoprotective and hypolipidemic effects.

体外研究

Ibrolipim (0.5-10 μM; 0-24 hours; THP-1 macrophage-derived foam cells) treatment increases ABCA1 and ABCG1 expression at translational levels in a dose-dependent and time-dependent manner .
Ibrolipim (0.5-10 μM; 0-24 hours; THP-1 macrophage-derived foam cells) treatment increases ABCA1 and ABCG1 expression at the transcriptional levels in a dose-dependent and time-dependent manner .
Ibrolipim 5 and 50 μmol/L significantly increases cholesterol efflux from THP-1 macrophage-derived foam cells to apoA-I or HDL. LXRα is also upregulated by the Ibrolipim treatment. LXRα small interfering RNA completely abolishes the promotion effect that is induced by Ibrolipim.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	THP-1 macrophage-derived foam cells
Concentration:	0.5 μM, 5 μM, 10 μM
Incubation Time:	0 hour, 6 hours, 12 hours, 24 hours
Result:	Increased ABCA1 and ABCG1 translational levels in a dose-dependent and time-dependent manner.

RT-PCR

Cell Line:	THP-1 macrophage-derived foam cells
Concentration:	0.5 μM, 5 μM, 10 μM
Incubation Time:	0 hour, 6 hours, 12 hours, 24 hours
Result:	Increased ABCA1 and ABCG1 expression at the transcriptional levels in a dose-dependent and time-dependent manner.

体内研究
(In Vivo)

Ibrolipim (NO-1886; 100 mg/kg; oral administration; daily; for 8 weeks; female Sprague-Dawley rats) treatment decreases accumulation of visceral fat and suppresses the increase in body weight resulting from the ovariectomy. Ibrolipim decreases the respiratory quotient and increases expression of the fatty acid translocase messenger RNA (mRNA) in the liver, soleus muscle, and mesenteric fat. Ibrolipim also increases the expression of fatty acid-binding protein mRNA in the liver and soleus muscle and the expression of the uncoupling protein 3 (UCP3) mRNA in the heart, soleus muscle, and mesenteric fat, but not in the brown adipose tissue.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Sprague-Dawley rats (10-week-old; 200-260 g) with experimental ovariectomy treatment
Dosage:	100 mg/kg
Administration:	Oral administration; daily; for 8 weeks
Result:	Decreased accumulation of visceral fat and suppressed the increase in body weight resulting from the ovariectomy.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Sprague-Dawley rats (10-week-old; 200-260 g) with experimental ovariectomy treatment
Dosage:	100 mg/kg
Administration:	Oral administration; daily; for 8 weeks
Result:	Decreased accumulation of visceral fat and suppressed the increase in body weight resulting from the ovariectomy.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Sprague-Dawley rats (10-week-old; 200-260 g) with experimental ovariectomy treatment
Dosage:	100 mg/kg
Administration:	Oral administration; daily; for 8 weeks
Result:	Decreased accumulation of visceral fat and suppressed the increase in body weight resulting from the ovariectomy.

性状

Solid

溶解性数据

In Vitro:

DMSO : 125 mg/mL (277.01 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.2161 mL	11.0803 mL	22.1607 mL
5 mM	0.4432 mL	2.2161 mL	4.4321 mL
10 mM	0.2216 mL	1.1080 mL	2.2161 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (4.61 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.61 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.61 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.61 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。